(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/171296 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07D 519/00* (2006.01)
C07D 498/22 (2006.01) *A61K 31/5025* (2006.01)
C07D 513/22 (2006.01)

(21) International Application Number:
PCT/US2025/015061

(22) International Filing Date:
07 February 2025 (07.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/551,943 09 February 2024 (09.02.2024) US
63/743,449 09 January 2025 (09.01.2025) US

(71) Applicant: **REVOLUTION MEDICINES, INC.** [US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **KNOX, John E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KOLTUN, Elena S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LATIMER, Bernadette K.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **MADEJ, Benjamin D.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **PARSONS, Dylan E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **THOMPSON, Severin**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **TOMLINSON, Aidan**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BUCKL, Andreas**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BURNETT, G. Leslie**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CREGG, James**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL, Adrian L.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LUU, Nguyen Hong Quang**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/171296 A1

(54) Title: RAS INHIBITORS

(57) Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.